The Swedish Brain Foundation (Hjärnfonden) awards grants to three DBB researchers
Professor Eva Hedlund, Professor Pål Stenmark and Professor Einar Hallberg at the Department of Biochemistry and Biophysics have been awarded grants from the Swedish Brain Foundation for their research into ALS, Epilepsy and Alzheimers.
Eva Hedlund. Pål Stenmark (Photo: Sören Andersson). Einar Hallberg.
Professor Eva Hedlund has received a grant for the project “Modeling ALS and investigating disease mechanisms using multi-tissue assembloids.”
Professor Hedlund’s lab at Stockholm University investigates mechanisms of neurodegenerative diseases with a focus on ALS, using stem cells and genome editing to model disease and single cell RNA sequencing methodologies to reveal early pathological mechanisms.
Professor Pål Stenmark's funding is for the project “Structure and function of SV2, the target of the antiepileptic drug Levetiracetam”.
Professor Stenmark’s group at Stockholm University focuses on questions related to human health using structural biology, biochemistry, molecular biology and biophysics.
Professor Einar Hallberg has received a grant for the project ” Ways to counteract loss of heterochromatin in neurodegeneration, especially frontotemporal dementia with parkinsonism (FTDP-17).”
Professor Hallberg’s lab at Stockholm University focuses on proteins in the inner nuclear membrane and has recently developed a novel imaging tool that allows systematic screening to identify proteins involved in in chromatin organization in the nuclear periphery.
We are focused on understanding mechanisms of selective neuronal vulnerability and resilience in neurodegenerative diseases, with particular emphasis on the lethal motor neuron disease amyotrophic lateral sclerosis (ALS).
The botulinum neurotoxins are the most toxic substances known. Despite this, their therapeutic properties are becoming increasingly evident. We study these toxins using a variety of methods, including X-ray crystallography, to understand their mechanism of action, thereby enabling the development of their therapeutic properties.
Human diseases such as cancer have been tied to proteins in Nuclear Pore Complexes (NPC). It has become increasingly clear that the proteins of the nuclear envelope orchestrate many functions involving cell signalling and chromatin organisation. The Hallberg Group is progressing on the path of discerning the nature of the pivotal role these proteins serve.
